Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
Authors
Keywords
-
Journal
Cancer Medicine
Volume 4, Issue 8, Pages 1205-1213
Publisher
Wiley
Online
2015-05-20
DOI
10.1002/cam4.475
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
- (2014) Richard Kefford et al. Journal of Translational Medicine
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
- (2014) James Larkin et al. LANCET ONCOLOGY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF in Melanoma: Current Strategies and Future Directions
- (2013) A. K. S. Salama et al. CLINICAL CANCER RESEARCH
- Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
- (2013) Reinhard Dummer et al. EUROPEAN JOURNAL OF CANCER
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Melanoma in the brain
- (2012) Geoffrey Thomas Gibney et al. MELANOMA RESEARCH
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- New Challenges in Endpoints for Drug Development in Advanced Melanoma
- (2011) A. Ribas et al. CLINICAL CANCER RESEARCH
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Determinants of survival in patients with brain metastases from cutaneous melanoma
- (2010) M Staudt et al. BRITISH JOURNAL OF CANCER
- Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma
- (2010) Thomas K. Eigentler et al. CANCER
- Prognostic factors for survival in melanoma patients with brain metastases
- (2010) Michael A. Davies et al. CANCER
- Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy
- (2010) J. J. Hong et al. CLINICAL CANCER RESEARCH
- Brain metastases: a medical neuro-oncology perspective
- (2010) Marc C Chamberlain Expert Review of Neurotherapeutics
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma
- (2008) Michael B. Atkins et al. CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started